ArticleWiener medizinische Wochenschrift (1946)2025
Characteristics of CBL-mutated patients with chronic myelomonocytic leukemia in a national (ABCMML) and an international cohort (cBIOPORTAL).
Article in Wiener medizinische Wochenschrift (1946), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The big data derived from major international collaborations now makes it possible to validate findings from traditional national patient cohorts in order to demonstrate consistency. We compared findings from CBL-mutated patients in the Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) with those in the CMML cohort recorded in cBIOPORTAL. CBL mutations were linked to shorter survival in the ABCMML cohort but not in the cBioPortal cohort. In neither cohort was there an association between AML-free survival and CBL mutations. Elevated leukocyte levels were observed in patients with CBL mutations in both cohorts. In neither cohort did hemoglobin values, platelet values, and circulating blast levels differ between patients with CBL mutations and those without. Data validation using two independent CMML cohorts ensures the quality standards for clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.